BWS Financial believes recent developments related to Biogen's (Nasdaq: BIIB) Tysabri have been "welcomed news". The firm maintains a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE